Business Wire

ALBACORE-CAPITAL-GRP

13.2.2020 11:02:04 CET | Business Wire | Press release

Share
AlbaCore Capital Group Confirms €1.5 Billion AUM1 for AlbaCore Partners II

European credit investment firm AlbaCore Capital Group (“AlbaCore”, “the Firm”), announced the successful close of its second fund, AlbaCore Partners II ICAV (“Fund II”), which has €1.5bn1 in total AUM. The Firm also recently announced plans for a debut CLO in 2020, which is currently in the warehousing phase. AlbaCore’s total AUM now stands at €3.6bn2 across its commingled and customised vehicles. The Firm’s investor base includes pension funds, sovereign wealth funds, endowments, insurance companies, consultants and family office investors, across Europe, North America, Middle East and Asia.

AlbaCore’s strategy focuses on bespoke private credit solutions for larger European companies, with the flexibility to opportunistically invest in secondary and primary markets when relative value is attractive. AlbaCore expects Fund II to be approximately 60% deployed at the end of February, after actively buying in the Q4 2018 credit market sell-off, and more recently shifting focus to primary and private markets. AlbaCore was the sole underwriter for subordinated debt related to two UK public-to-private transactions: BCA Marketplace (LSE: BCA - delisted) and Ei Group (LSE: EIG). Fund II gross IRR for 2019 was +20.6%.3

Bill Ammons, Founding Partner and Portfolio Manager, commented, “Our investing over the past fifteen months demonstrates the value of a flexible mandate in periods of market stress and also periods of resurging positive sentiment, as we saw in the second half of 2019. We are particularly excited about the recent BCA and Stonegate’s acquisition of Ei Group deals, which exemplify AlbaCore’s ability to provide unique, sizeable capital solutions that helped unlock the deals for the sponsor, while also providing an attractive risk/return to our investors.”

AlbaCore has built a 32-person team across its London and Dublin offices, and invests in a capital structure-agnostic manner, via a combination of senior secured loans, high yield bonds, private debt, and preferred equity. AlbaCore’s focus on generating consistent risk-adjusted returns across the capital structure and liquidity spectrum has generated 870bps of gross alpha over European credit markets across its two funds since inception4 .

AlbaCore champions a dynamic ESG approach which is well-integrated into the team’s investment decision making and ongoing risk monitoring. AlbaCore’s maiden CLO will also incorporate AlbaCore’s unique investment process and focus on ESG as part of its credit selection criteria.

Deborah Cohen Malka, Managing Director and Deputy Portfolio Manager, added, “ESG is a critical element of our Firm’s values and investment process. We continue to enhance the manner in which we implement ESG as part of our bottom up credit selection process. We also value our partners’ input to understand and incorporate their ESG ideas so we can continue to be a dynamic leader in credit investing and ESG related issues.”

David Allen, Founder and Chief Investment Officer, concluded: “AlbaCore is delighted and grateful for the opportunity to create new partnerships and expand upon existing relationships as we mature as a firm. We have come a long way since our founding in 2016, and we would not be where we are without our partners. Looking ahead we feel well positioned to continue to deliver strong risk-adjusted returns in 2020. We have an active private market pipeline, and dry powder to be opportunistic as markets digest the recent UK election results and navigate what could be an unpredictable year leading up to the US elections in November. We look forward to active and continued engagement with our partners in the coming year.”

About AlbaCore Capital Group

AlbaCore is a specialist European credit platform focused on European corporate credit markets. Founded in 2016, AlbaCore manages €3.6bn5 of AUM for global pension funds, insurance companies, family offices and endowments. AlbaCore takes a patient, long-term investment approach to private and opportunistic European credit markets. The credit selection process is based on fundamental research with a focus on capital preservation, ESG factors and risk-adjusted returns. Headquartered in London with an office in Dublin, AlbaCore is an organisation built on values, with a partnership approach alongside our investors and counterparties at our core.

www.AlbaCoreCapitalGroup.com

____________________
1 AUM is calculated as the sum of the Net Asset Value, undrawn capital commitments and available debt finance for Fund II as of 31 December 2019.
2 AUM is calculated as the sum of the Net Asset Value, undrawn capital commitments and available debt finance of all vehicles managed by AlbaCore.
3 Gross Internal Rate of Return (“IRR”) is calculated using fully equalised cash flows between Fund II and an investor as if all current investors had been committed to Fund II from inception. Rate of return calculated does not include management or performance fees, which would be reflected in a net internal rate of return (that would be lower) actually received by investors. Gross IRR is net of fund level expenses (including the costs of any such subscription line facility), but gross of management fees and performance fees. Past performance is not indicative of future results, which may vary.
4 Alpha generation is based on the gross composite IRR of AlbaCore Partners I ICAV and Fund II from inception of each fund to 31 December 2019 vs the blended IRR, assuming an equal weighting, of BAML Euro High Yield Index and S&P Euro Lev Loans Index as benchmarks for the performance of relative European credit markets.
5 AUM is calculated as the sum of the Net Asset Value, undrawn capital commitments and available debt finance of all vehicles managed by AlbaCore.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye